Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparing direct acting antivirals for hepatitis C using observational data - Why and how?

Pharmacology research & perspectives - 1 Oct 2020

Young Jim, Wong Stanley, Janjua Naveed Z, Klein Marina B

Abstract excerpt

The World Health Organisation's goal of hepatitis C virus (HCV) elimination by 2030 will require lower drug prices. Estimates of comparative efficacy promote competition between pharmaceutical companies but direct acting antivirals have been approved for the treatment of HCV without comparative trials. We emulated a randomized trial to answer the question of whether easy to treat patients with genotype 1 HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorenes

Share to Heterocyclic Compounds, 4 or More Rings

Share to Propensity Score

Share to Sofosbuvir

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 32894643
DOI: 10.1002/prp2.650
PMCID: PMC7507378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparing direct acting antivirals for hepatitis C using observational data - Why and how?PMID 32894643Read ↗

Hepatitis C: How Good Are Real-Life Data and Do Generics Work.Semantic proximity Read ↗

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Semantic proximity Read ↗

Analytic modeling to predict the outcome of chronic hepatitis C infection: a useful clinical tool or an unfair representation of natural history?Semantic proximity Read ↗

Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection.Semantic proximity Read ↗

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.Semantic proximity Read ↗

Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.Semantic proximity Read ↗

Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.Semantic proximity Read ↗

Modelling hepatitis C therapy—predicting effects of treatmentSemantic proximity Read ↗

Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.Semantic proximity Read ↗

Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataSemantic proximity Read ↗

Triangulating Instrumental Variable, confounder adjustment and difference-in-difference methods for comparative effectiveness research in observational dataSemantic proximity Read ↗

Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.